Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: A phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 2, 2011, Pages 492-498

  Koukourakis, Michael I ^a   Giatromanolaki, Alexandra ^a   Tsoutsou, Pelagia ^a   Lyratzopoulos, Nikolaos ^a   Pitiakoudis, Michael ^a   Kouklakis, George ^a   Chloropoulou, Pelagia A ^a   Manolas, Kostantinos ^a   Sivridis, Efthimios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Amifostine; Bevacizumab; Capecitabine; Radiotherapy; Rectal cancer

Indexed keywords

ACCELERATED RADIOTHERAPY; AMIFOSTINE; ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS; BEVACIZUMAB; CAPECITABINE; COLORECTAL CANCER; EXPERIMENTAL MODELS; PARTIAL RESPONSE; PATHOLOGIC COMPLETE RESPONSE; PHASE II; RADIOCHEMOTHERAPY; RECTAL CANCER; SKIN TOXICITY; THERAPEUTIC ACTIVITY;

ENZYME INHIBITION; PATHOLOGY; PATIENT MONITORING; RADIOTHERAPY; TOXICITY;

DISEASES;

AMIFOSTINE; BEVACIZUMAB; CAPECITABINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLADDER DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROCTALGIA; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM CARCINOMA; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; YOUNG ADULT;

EID: 79955642314     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.037     Document Type: Article

References (21)

1. A. Jemal, T. Murray, and E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30 (Pubitemid 40310185)
2. K.M. Tveit, and V.V. Kataja ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of rectal cancer Ann Oncol 16 Suppl. 1 2005 i20 i22
3. Improved survival with preoperative radiotherapy in resectable rectal cancer Swedish Rectal Cancer Trial N Engl J Med 336 1997 980 987
4. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
5. I.D. Nagtegaal, C.J. van de Velde, and C.A. Marijnen Low rectal cancer: A call for a change of approach in abdominoperineal resection J Clin Oncol 23 2005 9257 9264
6. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123 (Pubitemid 44394918)
7. A. Giatromanolaki, E. Sivridis, and M.I. Koukourakis Angiogenesis in colorectal cancer: Prognostic and therapeutic implications Am J Clin Oncol 29 2006 408 417 (Pubitemid 44197549)
8. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
9. D.H. Gorski, M.A. Beckett, and N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378 (Pubitemid 29334495)
10. L. Geng, E. Donnelly, and G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419 (Pubitemid 32685816)
11. M.I. Koukourakis, C. Simopoulos, and M. Pitiakoudis Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: A feasibility study Anticancer Res 28 2008 3035 3040
12. M. Koukourakis, G. Hlouverakis, and L. Kosma The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma Int J Radiat Oncol Biol Phys 34 1996 315 322 (Pubitemid 26031576)
13. B. Macejewski, J.M. Taylor, and H.R. Wither Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx Radiother Oncol 7 1986 323 326 (Pubitemid 17232171)
14. R. Suwinski, I. Wzietek, and R. Tarnawski Moderately low alpha/beta ratio for rectal cancer may best explain the outcome of three fractionation schedules of preoperative radiotherapy Int J Radiat Oncol Biol Phys 69 2007 793 799 (Pubitemid 47418389)
15. M.I. Koukourakis, I. Abatzoglou, and L. Sivridis Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy Anticancer Res 26 2006 2437 2443 (Pubitemid 43980214)
16. C.G. Willett, S.V. Kozin, and D.G. Duda Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice Semin Oncol 33 2006 S35 S40
17. M.I. Koukourakis, I. Mavanis, and G. Kouklakis Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging Am J Clin Oncol 30 2007 315 318 (Pubitemid 46884155)
18. M.I. Koukourakis, A. Giatromanolaki, and H. Sheldon Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: Vasculature-independent radiosensitizing effect of bevacizumab Clin Cancer Res 15 2009 7069 7076
19. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
20. C.H. Crane, C. Eng, and B.W. Feig Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 76 2010 824 830
21. C.G. Willett, D.G. Duda, and E. di Tomaso Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study J Clin Oncol 27 2009 3020 3026